You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
Luminex said that with two FDA EUAs it is now providing SARS-CoV-2 diagnostic tests for high-complexity, high-throughput labs and moderate-complexity testing facilities.
The Aries SARS-CoV-2 assay provides results in approximately two hours and can be run on Luminex's sample-to-answer Aries Systems.
The NxTag CoV Extended Panel is a multiplex PCR test that uses the company's bead-based NxTag technology to detect coronavirus in nasopharyngeal swab specimens.
Of the 28 companies in the index, nine companies' share prices increased while the share values of 19 declined month over month.
The company said it expects to launch the Verigene II system with respiratory and gastrointestinal assays in the middle of this year.
News items for the in vitro diagnostics industry for the week of Feb. 17, 2020.
The firm said that its Verigene II multiplex system is on track to launch in mid-2020 among a number of new products scheduled for release this year.
Qiagen, which is also developing a single-plex qRT-PCR assay for SARS-CoV-2, said it will have a syndromic panel including targets for the virus ready this month.
The firm submitted its Verigene II Gastrointestinal Flex Assay to the FDA in Q4 and expects to submit Verigene II Respiratory Flex Assay to the agency in Q1 2020.
Abbott highlighted its next-generation Alinity platforms, and Caris discussed its plans to provide precision oncology services.